Ludwig Schlemm
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ludwig Schlemm has a total of 183 co-authors. Here are the top co-authors by number of shared publications:
- Christian H. Nolte
Department of Neurology with Experimental Neurology, Charité Universitätsmedizin Berlin, Berlin, Germany
11 shared publications Matthias Endres
Department of Neurology, Charité - Universitätsmedizin Berlin, Berlin, Germany
11 shared publicationsMartin Ebinger
Center for Stroke Research Berlin (CSB), Charité – Universitätsmedizin Berlin, Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany
7 shared publications- Matthias Endres
Center for Stroke Research Berlin (CSB), Charité-Universitätsmedizin Berlin, Berlin, Germany
6 shared publications - Berthold Hocher
Fifth Department of Medicine (Nephrology/Endocrinology/Rheumatology/Pneumology), University Medical Centre Mannheim, University of Heidelberg
5 shared publications Thiemo Pfab
Center for Cardiovascular Research, Institute of Pharmacology
5 shared publications
Latest Publications
- 11 November 2025
- Published by Wolters Kluwer Health in Neurology
- Vol. 105 (9) , e214225
Effect of Mobile Stroke Unit Dispatch on Process Parameters and Functional Outcomes in Patients With Acute Stroke
Prehospital stroke management on mobile stroke units (MSUs) shortens time to IV thrombolysis (IVT) and improves functional outcomes. Because IVT effects are time-dependent, optimizing workflows and dispatch-related processes may enhance MSU benefits. The B_PROUD-2.0 study aimed to determine the effect of additional MSU dispatch on functional outcomes in acute stroke patients under optimized MSU organization and service delivery. In the nonrandomized, controlled B_PROUD-2.0 study (May 2019-April 2021) conducted in Berlin, Germany, MSUs were simultaneously dispatched with conventional care ambulances for suspected stroke emergency calls, whenever available. We compared outcomes and process parameters between dispatch groups (additional MSU dispatch vs conventional care only) among patients with cerebral ischemia with disabling neurologic symptoms and no contraindications to reperfusion treatments. We used data from the Berlin dispatch center and records from the B_SPATIAL registry, consisting of 15 Berlin hospitals with stroke units. We performed pooled analyses with the B_PROUD-1.0 primary population (February 2017-April 2021) and with an extended cohort that also included patients with reperfusion treatment contraindications. The primary and co-primary outcomes were 3-month modified Rankin Scale scores (0: no deficits to 6: death) and 3-tiered disability scale scores. Effect estimates for these outcomes were obtained from ordinal logistic regressions, adjusting for a priori selected covariates after multiple imputation for missing values. Coronavirus disease 2019 pandemic and limited funding hindered full implementation of procedural improvements. A total of 1,050 patients (mean age: 74 years, 46.7% female) were included in B_PROUD-2.0 (vs 1,500 planned). We found no statistically significant effect of MSU dispatch on primary (common odds ratio [cOR] 0.90, 95% CI 0.72-1.14) or co-primary (cOR 0.86, 95% CI 0.63-1.17) outcomes in B_PROUD-2.0, and higher odds of IVT ≤1 hour of dispatch in the MSU group (OR 10.15, 95% CI 7.10-14.51). In pooled B_PROUD-1.0+2.0 primary population analyses (N = 2,666, mean age: 73 years, 46.8% female), we found a beneficial effect on primary (cOR 0.80, 95% CI 0.67-0.96) and co-primary (cOR 0.79, 95% CI 0.64-0.97) outcomes. The average effect on all stroke/TIA patients in the extended cohort (N = 4,336, mean age 75 years, 47.6% female) was also favorable (primary cOR 0.85, 95% CI 0.75-0.95; co-primary cOR 0.86, 95% CI 0.75-0.99). While we did not observe statistically significant differences in functional outcomes in the underpowered B_PROUD-2.0 study, we found beneficial effects considering both B_PROUD study periods, also when including all stroke/TIA patients. ClinicalTrials.gov: NCT03931616. Registered: April 26, 2019. First patient enrolled: May 9, 2019. The B_PROUD-2.0 study provides Class III evidence that the addition of MSUs to conventional care ambulances did not improve functional outcomes at 3 months compared with conventional care ambulances alone in patients with acute ischemic stroke.
- 11 November 2025
- Published by Wolters Kluwer Health in Neurology
- Vol. 105 (9) , e214225
Effect of Mobile Stroke Unit Dispatch on Process Parameters and Functional Outcomes in Patients With Acute Stroke
Prehospital stroke management on mobile stroke units (MSUs) shortens time to IV thrombolysis (IVT) and improves functional outcomes. Because IVT effects are time-dependent, optimizing workflows and dispatch-related processes may enhance MSU benefits. The B_PROUD-2.0 study aimed to determine the effect of additional MSU dispatch on functional outcomes in acute stroke patients under optimized MSU organization and service delivery. In the nonrandomized, controlled B_PROUD-2.0 study (May 2019-April 2021) conducted in Berlin, Germany, MSUs were simultaneously dispatched with conventional care ambulances for suspected stroke emergency calls, whenever available. We compared outcomes and process parameters between dispatch groups (additional MSU dispatch vs conventional care only) among patients with cerebral ischemia with disabling neurologic symptoms and no contraindications to reperfusion treatments. We used data from the Berlin dispatch center and records from the B_SPATIAL registry, consisting of 15 Berlin hospitals with stroke units. We performed pooled analyses with the B_PROUD-1.0 primary population (February 2017-April 2021) and with an extended cohort that also included patients with reperfusion treatment contraindications. The primary and co-primary outcomes were 3-month modified Rankin Scale scores (0: no deficits to 6: death) and 3-tiered disability scale scores. Effect estimates for these outcomes were obtained from ordinal logistic regressions, adjusting for a priori selected covariates after multiple imputation for missing values. Coronavirus disease 2019 pandemic and limited funding hindered full implementation of procedural improvements. A total of 1,050 patients (mean age: 74 years, 46.7% female) were included in B_PROUD-2.0 (vs 1,500 planned). We found no statistically significant effect of MSU dispatch on primary (common odds ratio [cOR] 0.90, 95% CI 0.72-1.14) or co-primary (cOR 0.86, 95% CI 0.63-1.17) outcomes in B_PROUD-2.0, and higher odds of IVT ≤1 hour of dispatch in the MSU group (OR 10.15, 95% CI 7.10-14.51). In pooled B_PROUD-1.0+2.0 primary population analyses (N = 2,666, mean age: 73 years, 46.8% female), we found a beneficial effect on primary (cOR 0.80, 95% CI 0.67-0.96) and co-primary (cOR 0.79, 95% CI 0.64-0.97) outcomes. The average effect on all stroke/TIA patients in the extended cohort (N = 4,336, mean age 75 years, 47.6% female) was also favorable (primary cOR 0.85, 95% CI 0.75-0.95; co-primary cOR 0.86, 95% CI 0.75-0.99). While we did not observe statistically significant differences in functional outcomes in the underpowered B_PROUD-2.0 study, we found beneficial effects considering both B_PROUD study periods, also when including all stroke/TIA patients. ClinicalTrials.gov: NCT03931616. Registered: April 26, 2019. First patient enrolled: May 9, 2019. The B_PROUD-2.0 study provides Class III evidence that the addition of MSUs to conventional care ambulances did not improve functional outcomes at 3 months compared with conventional care ambulances alone in patients with acute ischemic stroke.
- Open Access
- 1 September 2023
- Published by Oxford University Press (OUP) in European Stroke Journal
- Vol. 8 (3) , 610-617
Decline of thrombolysis rates before endovascular therapy in patients with acute anterior circulation large vessel occlusion ischemic stroke: A multicenter analysis from the German Stroke Registry
Introduction: In recent years, the role of intravenous thrombolysis (IVT) before endovascular stroke treatment (EVT) has been discussed intensively. Whether the discussion was accompanied by changing rates of bridging IVT is unknown. Methods: Data were extracted from the prospectively maintained German Stroke Registry, including patients treated with EVT at one of 28 stroke centers in Germany between 2016 and 2021. Primary outcome parameters were the rate of bridging IVT (a) in the entire registry cohort and (b) in patients without formal contraindications to IVT (i.e. recent oral anticoagulants, time window ⩾4.5 h, extensive early ischemic changes) adjusted for demographic and clinical confounders. Results: 10,162 patients (52.8% women, median age 77 years, median National Institutes of Health Stroke Scale score 14) were analyzed. In the entire cohort, the rate of bridging IVT decreased from 63.8% in 2016 to 43.6% in 2021 (average absolute annual decrease 3.1%, 95% CI 2.4%–3.8%), while the proportion of patients with at least one formal contraindication increased by only 1.2% annually (95% CI 0.6%–1.9%). Among 5460 patients without record of formal contraindications, the rate of bridging IVT decreased from 75.5% in 2016 to 63.2% in 2021 and was significantly associated with admission date in a multivariable model (average absolute annual decrease 1.4%, 95% CI 0.6%–2.2%). Clinical factors associated with lower odds of bridging IVT included diabetes mellitus, carotid-T-occlusion, dual antiplatelet therapy, and direct admission to a thrombectomy center. Conclusion: We observed a substantial decline in bridging IVT rates independent of demographic confounders and not explained by an increase in contraindications. This observation deserves further exploration in independent populations.
- 1 September 2023
- Published by Oxford University Press (OUP) in European Stroke Journal
- Vol. 8 (3) , 610-617
Open AccessDecline of thrombolysis rates before endovascular therapy in patients with acute anterior circulation large vessel occlusion ischemic stroke: A multicenter analysis from the German Stroke Registry
Introduction: In recent years, the role of intravenous thrombolysis (IVT) before endovascular stroke treatment (EVT) has been discussed intensively. Whether the discussion was accompanied by changing rates of bridging IVT is unknown. Methods: Data were extracted from the prospectively maintained German Stroke Registry, including patients treated with EVT at one of 28 stroke centers in Germany between 2016 and 2021. Primary outcome parameters were the rate of bridging IVT (a) in the entire registry cohort and (b) in patients without formal contraindications to IVT (i.e. recent oral anticoagulants, time window ⩾4.5 h, extensive early ischemic changes) adjusted for demographic and clinical confounders. Results: 10,162 patients (52.8% women, median age 77 years, median National Institutes of Health Stroke Scale score 14) were analyzed. In the entire cohort, the rate of bridging IVT decreased from 63.8% in 2016 to 43.6% in 2021 (average absolute annual decrease 3.1%, 95% CI 2.4%–3.8%), while the proportion of patients with at least one formal contraindication increased by only 1.2% annually (95% CI 0.6%–1.9%). Among 5460 patients without record of formal contraindications, the rate of bridging IVT decreased from 75.5% in 2016 to 63.2% in 2021 and was significantly associated with admission date in a multivariable model (average absolute annual decrease 1.4%, 95% CI 0.6%–2.2%). Clinical factors associated with lower odds of bridging IVT included diabetes mellitus, carotid-T-occlusion, dual antiplatelet therapy, and direct admission to a thrombectomy center. Conclusion: We observed a substantial decline in bridging IVT rates independent of demographic confounders and not explained by an increase in contraindications. This observation deserves further exploration in independent populations.
- Open Access
Datawarehouse-enabled quality control of atrial fibrillation detection in the stroke unit setting
- Open Access
- 2 December 2022
- Published by Wiley in Annals of Neurology
- Vol. 93 (3) , 511-521
A Managed Care System with Telemedicine Support for Neurological Emergencies
Objectives: Telemedicine is frequently used to provide remote neurological expertise for acute stroke workup and was associated with better functional outcomes when combined with a stroke unit system‐of‐care. We investigated whether such system‐of‐care yields additional benefits when implemented on top of neurological competence already available onsite.Methods: Quality improvement measures were implemented within a “hub‐and‐spoke” teleneurology network in 11 hospitals already provided with onsite or telestroke expertise. Measures included dedicated units for neurological emergencies, standardization of procedures, multiprofessional training, and quality‐of‐care monitoring. Intervention effects were investigated in a controlled study enrolling patients insured at 3 participating statutory health insurances diagnosed with acute stroke or other neurological emergencies. Outcomes during the intervention period between November 2017 and February 2020 were compared with those pre‐intervention between October 2014 and March 2017. To control for temporal trends, we compared outcomes of patients with respective diagnoses in 11 hospitals of the same region. Primary outcome was the composite of up‐to‐90‐day death, new disability with the need of ambulatory or nursing home care, expressed by adjusted hazard ratio (aHR).Results: We included 1,418 patients post‐implementation (55% female, mean age 76.7 ± 12.8 year) and 2,306 patients pre‐implementation (56%, 75.8 ± 13.0 year, respectively). The primary outcome occurred in 479/1,418 (33.8%) patients post‐implementation and in 829/2,306 (35.9%) pre‐implementation. The aHR for the primary outcome was 0.89 (95% confidence interval [CI]: 0.79–0.99, p = 0.04) with no improvement seen in non‐participating hospitals between post‐ versus pre‐implementation periods (aHR 1.04; 95% CI: 0.95–1.15).Interpretation: Implementation of a multicomponent system‐of‐care was associated with a lower risk of poor outcomes. ANN NEUROL 2023;93:511–521
- 2 December 2022
- Published by Wiley in Annals of Neurology
- Vol. 93 (3) , 511-521
Open AccessA Managed Care System with Telemedicine Support for Neurological Emergencies
Objectives: Telemedicine is frequently used to provide remote neurological expertise for acute stroke workup and was associated with better functional outcomes when combined with a stroke unit system‐of‐care. We investigated whether such system‐of‐care yields additional benefits when implemented on top of neurological competence already available onsite.Methods: Quality improvement measures were implemented within a “hub‐and‐spoke” teleneurology network in 11 hospitals already provided with onsite or telestroke expertise. Measures included dedicated units for neurological emergencies, standardization of procedures, multiprofessional training, and quality‐of‐care monitoring. Intervention effects were investigated in a controlled study enrolling patients insured at 3 participating statutory health insurances diagnosed with acute stroke or other neurological emergencies. Outcomes during the intervention period between November 2017 and February 2020 were compared with those pre‐intervention between October 2014 and March 2017. To control for temporal trends, we compared outcomes of patients with respective diagnoses in 11 hospitals of the same region. Primary outcome was the composite of up‐to‐90‐day death, new disability with the need of ambulatory or nursing home care, expressed by adjusted hazard ratio (aHR).Results: We included 1,418 patients post‐implementation (55% female, mean age 76.7 ± 12.8 year) and 2,306 patients pre‐implementation (56%, 75.8 ± 13.0 year, respectively). The primary outcome occurred in 479/1,418 (33.8%) patients post‐implementation and in 829/2,306 (35.9%) pre‐implementation. The aHR for the primary outcome was 0.89 (95% confidence interval [CI]: 0.79–0.99, p = 0.04) with no improvement seen in non‐participating hospitals between post‐ versus pre‐implementation periods (aHR 1.04; 95% CI: 0.95–1.15).Interpretation: Implementation of a multicomponent system‐of‐care was associated with a lower risk of poor outcomes. ANN NEUROL 2023;93:511–521
- Open Access
- 19 May 2022
- Published by Springer Nature in Journal of Neurology
- Vol. 269 (10) , 5660-5667
New remote cerebral microbleeds in acute ischemic stroke: an analysis of the randomized, placebo-controlled WAKE-UP trial
- 19 May 2022
- Published by Springer Nature in Journal of Neurology
- Vol. 269 (10) , 5660-5667
Open AccessNew remote cerebral microbleeds in acute ischemic stroke: an analysis of the randomized, placebo-controlled WAKE-UP trial
- 10 May 2022
- Published by Wolters Kluwer Health in Neurology
- Vol. 98 (19) , 817
Author Response: Cerebral Microbleeds and Treatment Effect of Intravenous Thrombolysis in Acute Stroke: An Analysis of the WAKE-UP Randomized Clinical Trial
- 10 May 2022
- Published by Wolters Kluwer Health in Neurology
- Vol. 98 (19) , 817
Author Response: Cerebral Microbleeds and Treatment Effect of Intravenous Thrombolysis in Acute Stroke: An Analysis of the WAKE-UP Randomized Clinical Trial
- Open Access
- 18 January 2022
- Published by Wolters Kluwer Health in Neurology
- Vol. 98 (3) , e302-e314
Cerebral Microbleeds and Treatment Effect of Intravenous Thrombolysis in Acute Stroke
Background and Objectives Cerebral microbleeds (CMBs) are common in patients with acute ischemic stroke and are associated with increased risk of intracerebral hemorrhage (ICH) after intravenous thrombolysis. Whether CMBs modify the treatment effect of thrombolysis is unknown. Methods We performed a prespecified analysis of the prospective randomized controlled multicenter Efficacy and Safety of MRI-Based Thrombolysis in Wake-Up Stroke (WAKE-UP) trial including patients with acute ischemic stroke with unknown time of symptom onset and diffusion-weighted imaging–fluid-attenuated inversion recovery mismatch on MRI receiving alteplase or placebo. Patients were screened and enrolled between September 2012 and June 2017 (with final follow-up in September 2017). Patients were randomized to treatment with IV thrombolysis with alteplase at 0.9 mg/kg body weight or placebo. CMB status (presence, number, and distribution) was assessed after study completion by 3 raters blinded to clinical information following a standardized protocol. Outcome measures were excellent functional outcome at 90 days, defined by modified Rankin Scale (mRS) score ≤1, and symptomatic ICH according to National Institutes of Neurological Disease and Stroke trial criteria 22 to 36 hours after treatment. Results Of 503 patients enrolled in the WAKE-UP trial, 459 (91.3%; 288 [63%] men) were available for analysis. Ninety-eight (21.4%) had at least 1 CMB on baseline imaging; 45 (9.8%) had exactly 1 CMB; 37 (8.1%) had 2 to 4 CMBs; and 16 (3.5%) had ≥5 CMBs. Presence of CMBs was associated with a nonsignificant increased risk of symptomatic ICH (11.2% vs 4.2%; adjusted odds ratio [OR] 2.32, 95% confidence interval [CI] 0.99–5.43, p = 0.052) but had no effect on functional outcome at 90 days (mRS score ≤1: 45.8% vs 50.7%; adjusted OR 0.99, 95% CI 0.59–1.64, p = 0.955). Patients receiving alteplase had better functional outcome (mRS score ≤1: 54.6% vs 44.6%, adjusted OR 1.61, 95% CI 1.07–2.43, p = 0.022) without evidence of heterogeneity in relation to CMB presence (p of the interactive term = 0.546). Results were similar for subpopulations with strictly lobar (presumed cerebral amyloid angiopathy related) or not strictly lobar CMB distribution. Discussion In the randomized-controlled WAKE-UP trial, we saw no evidence of reduced treatment effect of alteplase in patients with acute ischemic stroke with ≥1 CMBs. Additional studies are needed to determine the treatment effect of alteplase and its benefit-harm ratio in patients with a larger number of CMBs. Trial Registration Information ClinicalTrials.gov identifier NCT01525290; ClinicalTrialsRegister.EU identifier 2011-005906-32. Classification of Evidence This study provides Class II evidence that for patients with acute ischemic stroke with unknown time of onset and diffusion-weighted imaging–fluid-attenuated inversion recovery mismatch who received IV alteplase, CMBs are not significantly associated with functional outcome at 90 days.
- 18 January 2022
- Published by Wolters Kluwer Health in Neurology
- Vol. 98 (3) , e302-e314
Open AccessCerebral Microbleeds and Treatment Effect of Intravenous Thrombolysis in Acute Stroke
Background and Objectives Cerebral microbleeds (CMBs) are common in patients with acute ischemic stroke and are associated with increased risk of intracerebral hemorrhage (ICH) after intravenous thrombolysis. Whether CMBs modify the treatment effect of thrombolysis is unknown. Methods We performed a prespecified analysis of the prospective randomized controlled multicenter Efficacy and Safety of MRI-Based Thrombolysis in Wake-Up Stroke (WAKE-UP) trial including patients with acute ischemic stroke with unknown time of symptom onset and diffusion-weighted imaging–fluid-attenuated inversion recovery mismatch on MRI receiving alteplase or placebo. Patients were screened and enrolled between September 2012 and June 2017 (with final follow-up in September 2017). Patients were randomized to treatment with IV thrombolysis with alteplase at 0.9 mg/kg body weight or placebo. CMB status (presence, number, and distribution) was assessed after study completion by 3 raters blinded to clinical information following a standardized protocol. Outcome measures were excellent functional outcome at 90 days, defined by modified Rankin Scale (mRS) score ≤1, and symptomatic ICH according to National Institutes of Neurological Disease and Stroke trial criteria 22 to 36 hours after treatment. Results Of 503 patients enrolled in the WAKE-UP trial, 459 (91.3%; 288 [63%] men) were available for analysis. Ninety-eight (21.4%) had at least 1 CMB on baseline imaging; 45 (9.8%) had exactly 1 CMB; 37 (8.1%) had 2 to 4 CMBs; and 16 (3.5%) had ≥5 CMBs. Presence of CMBs was associated with a nonsignificant increased risk of symptomatic ICH (11.2% vs 4.2%; adjusted odds ratio [OR] 2.32, 95% confidence interval [CI] 0.99–5.43, p = 0.052) but had no effect on functional outcome at 90 days (mRS score ≤1: 45.8% vs 50.7%; adjusted OR 0.99, 95% CI 0.59–1.64, p = 0.955). Patients receiving alteplase had better functional outcome (mRS score ≤1: 54.6% vs 44.6%, adjusted OR 1.61, 95% CI 1.07–2.43, p = 0.022) without evidence of heterogeneity in relation to CMB presence (p of the interactive term = 0.546). Results were similar for subpopulations with strictly lobar (presumed cerebral amyloid angiopathy related) or not strictly lobar CMB distribution. Discussion In the randomized-controlled WAKE-UP trial, we saw no evidence of reduced treatment effect of alteplase in patients with acute ischemic stroke with ≥1 CMBs. Additional studies are needed to determine the treatment effect of alteplase and its benefit-harm ratio in patients with a larger number of CMBs. Trial Registration Information ClinicalTrials.gov identifier NCT01525290; ClinicalTrialsRegister.EU identifier 2011-005906-32. Classification of Evidence This study provides Class II evidence that for patients with acute ischemic stroke with unknown time of onset and diffusion-weighted imaging–fluid-attenuated inversion recovery mismatch who received IV alteplase, CMBs are not significantly associated with functional outcome at 90 days.
- Open Access
- 3 May 2021
- Published by Springer Nature in Neurological Research and Practice
- Vol. 3 (1) , 1-9
Mechanical thrombectomy in patients with cervical artery dissection and stroke in the anterior or posterior circulation – a multicenter analysis from the German Stroke Registry
Background: Cervical artery dissection (CAD) is a rare cause of acute ischemic stroke (AIS) with large vessel occlusion (LVO) and may constitute a challenge for mechanical thrombectomy (MT). We compared procedural characteristics, reperfusion rates, and clinical outcome in AIS patients undergoing MT with and without CAD.Methods: We performed a pre-specified analysis of patients registered within the German Stroke Registry, a prospectively maintained multicenter registry of consecutive patients with AIS patients treated by MT. Procedural characteristics included time periods and additional application of medication.Results: Of 2589 patients, 62 (2.4%) were diagnosed with CAD. CAD patients were younger, had lower rates of known vascular risk factors and larger baseline stroke volumes. MT in CAD patients took significantly longer (median [IQR] groin-puncture-to-flow restoration time: 98 [67–136] versus 70 [45–100] minutes;p < 0.001) and more often required use of intra-arterial medication (34.4% versus 15.6%;p < 0.001). Reperfusion success (modified Treatment in Cerebral Infarction score 2b-3: 85.2% versus 83.3%,p = 0.690) and favorable functional outcome after 3 months (modified Rankin Scale score ≤ 2: 70.9% versus 36.4%, adjustedp = 0.086) did not differ significantly between patients with and without CAD. The latter findings held true for both CAD in the anterior and posterior circulation.Conclusion: CAD in AIS requiring MT is rare. MT in patients with CAD constitutes a particular procedural challenge, but still achieves favorable radiological and functional outcomes in most patients. Our data provide indirect evidence that MT is of clinical benefit in patients with AIS due to LVO and CAD.
- 3 May 2021
- Published by Springer Nature in Neurological Research and Practice
- Vol. 3 (1) , 1-9
Open AccessMechanical thrombectomy in patients with cervical artery dissection and stroke in the anterior or posterior circulation – a multicenter analysis from the German Stroke Registry
Background: Cervical artery dissection (CAD) is a rare cause of acute ischemic stroke (AIS) with large vessel occlusion (LVO) and may constitute a challenge for mechanical thrombectomy (MT). We compared procedural characteristics, reperfusion rates, and clinical outcome in AIS patients undergoing MT with and without CAD.Methods: We performed a pre-specified analysis of patients registered within the German Stroke Registry, a prospectively maintained multicenter registry of consecutive patients with AIS patients treated by MT. Procedural characteristics included time periods and additional application of medication.Results: Of 2589 patients, 62 (2.4%) were diagnosed with CAD. CAD patients were younger, had lower rates of known vascular risk factors and larger baseline stroke volumes. MT in CAD patients took significantly longer (median [IQR] groin-puncture-to-flow restoration time: 98 [67–136] versus 70 [45–100] minutes;p < 0.001) and more often required use of intra-arterial medication (34.4% versus 15.6%;p < 0.001). Reperfusion success (modified Treatment in Cerebral Infarction score 2b-3: 85.2% versus 83.3%,p = 0.690) and favorable functional outcome after 3 months (modified Rankin Scale score ≤ 2: 70.9% versus 36.4%, adjustedp = 0.086) did not differ significantly between patients with and without CAD. The latter findings held true for both CAD in the anterior and posterior circulation.Conclusion: CAD in AIS requiring MT is rare. MT in patients with CAD constitutes a particular procedural challenge, but still achieves favorable radiological and functional outcomes in most patients. Our data provide indirect evidence that MT is of clinical benefit in patients with AIS due to LVO and CAD.
- 1 April 2021
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Quality and Outcomes
- Vol. 14 (4)
Cost Effectiveness of Interhospital Transfer for Mechanical Thrombectomy of Acute Large Vessel Occlusion Stroke
Background: Emergency interhospital transfer of patients with stroke with large vessel occlusion to a comprehensive stroke center for mechanical thrombectomy is resource-intensive and can be logistically challenging. Imaging markers may identify patients in whom intravenous thrombolysis (IVT) alone is likely to result in thrombus resolution, potentially rendering interhospital transfers unnecessary. Here, we investigate how predicted probabilities to achieve IVT-mediated recanalization affect cost-effectiveness estimates of interhospital transfer. Methods: We performed a health economic analysis comparing emergency interhospital transfer of patients with acute large vessel occlusion stroke after administration of IVT with a scenario in which patients also receive IVT but remain at the primary hospital. Results were stratified by clinical parameters, treatment delays, and the predicted probability to achieve IVT-mediated recanalization. Estimated 3-month outcomes were combined with a long-term probabilistic model to yield quality-adjusted life years (QALYs) and costs. Uncertainty was quantified in probabilistic sensitivity analyses. Results: Depending on input parameters, marginal costs of interhospital transfer ranged from USD −61 366 (cost saving) to USD +20 443 and additional QALYs gained from 0.1 to 3.0, yielding incremental cost-effectiveness ratios of <USD 0 (dominant) to USD 310 000 per QALY. For some elderly patients with moderate or severe stroke symptoms treated in a remote primary stroke center, transfer was unlikely to be cost effective at a willingness-to-pay threshold of USD 100 000 and 50 000 per QALY (20% and 1%, respectively) if the predicted probability to achieve IVT-related recanalization was high. On the other hand, in some younger patients, the analysis yielded incremental cost-effectiveness ratio estimates below USD 20 000 per QALY independent of the predicted recanalization rate. Conclusions: Predicted probabilities to achieve IVT-mediated recanalization significantly affect the cost-effectiveness of interhospital transfer for MT, in particular in elderly patients with moderate or severe stroke symptoms. However, high predicted recanalization rates alone do not generally imply that patients should not be considered for transfer.
- 1 April 2021
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Quality and Outcomes
- Vol. 14 (4)
Cost Effectiveness of Interhospital Transfer for Mechanical Thrombectomy of Acute Large Vessel Occlusion Stroke
Background: Emergency interhospital transfer of patients with stroke with large vessel occlusion to a comprehensive stroke center for mechanical thrombectomy is resource-intensive and can be logistically challenging. Imaging markers may identify patients in whom intravenous thrombolysis (IVT) alone is likely to result in thrombus resolution, potentially rendering interhospital transfers unnecessary. Here, we investigate how predicted probabilities to achieve IVT-mediated recanalization affect cost-effectiveness estimates of interhospital transfer. Methods: We performed a health economic analysis comparing emergency interhospital transfer of patients with acute large vessel occlusion stroke after administration of IVT with a scenario in which patients also receive IVT but remain at the primary hospital. Results were stratified by clinical parameters, treatment delays, and the predicted probability to achieve IVT-mediated recanalization. Estimated 3-month outcomes were combined with a long-term probabilistic model to yield quality-adjusted life years (QALYs) and costs. Uncertainty was quantified in probabilistic sensitivity analyses. Results: Depending on input parameters, marginal costs of interhospital transfer ranged from USD −61 366 (cost saving) to USD +20 443 and additional QALYs gained from 0.1 to 3.0, yielding incremental cost-effectiveness ratios of <USD 0 (dominant) to USD 310 000 per QALY. For some elderly patients with moderate or severe stroke symptoms treated in a remote primary stroke center, transfer was unlikely to be cost effective at a willingness-to-pay threshold of USD 100 000 and 50 000 per QALY (20% and 1%, respectively) if the predicted probability to achieve IVT-related recanalization was high. On the other hand, in some younger patients, the analysis yielded incremental cost-effectiveness ratio estimates below USD 20 000 per QALY independent of the predicted recanalization rate. Conclusions: Predicted probabilities to achieve IVT-mediated recanalization significantly affect the cost-effectiveness of interhospital transfer for MT, in particular in elderly patients with moderate or severe stroke symptoms. However, high predicted recanalization rates alone do not generally imply that patients should not be considered for transfer.
- 20 January 2021
- Published by SAGE Publications in International Journal of Stroke
- Vol. 16 (8) , 953-961
How do treatment times impact on functional outcome in stroke patients undergoing thrombectomy in Germany? Results from the German Stroke Registry
Background: Functional outcome post-stroke depends on time to recanalization. Effect of in-hospital delay may differ in patients directly admitted to a comprehensive stroke center and patients transferred via a primary stroke center. We analyzed the current door-to-groin time in Germany and explored its effect on functional outcome in a real-world setting. Methods: Data were collected in 25 stroke centers in the German Stroke Registry-Endovascular Treatment a prospective, multicenter, observational registry study including stroke patients with large vessel occlusion. Functional outcome was assessed at three months by modified Rankin Scale. Association of door-to-groin time with outcome was calculated using binary logistic regression models. Results: Out of 4340 patients, 56% were treated primarily in a comprehensive stroke center and 44% in a primary stroke center and then transferred to a comprehensive stroke center (“drip-and-ship” concept). Median onset-to-arrival at comprehensive stroke center time and door-to-groin time were 103 and 79 min in comprehensive stroke center patients and 225 and 44 min in primary stroke center patients. The odds ratio for poor functional outcome per hour of onset-to-arrival-at comprehensive stroke center time was 1.03 (95%CI 1.01–1.05) in comprehensive stroke center patients and 1.06 (95%CI 1.03–1.09) in primary stroke center patients. The odds ratio for poor functional outcome per hour of door-to-groin time was 1.30 (95%CI 1.16–1.46) in comprehensive stroke center patients and 1.04 (95%CI 0.89–1.21) in primary stroke center patients. Longer door-to-groin time in comprehensive stroke center patients was associated with admission on weekends (odds ratio 1.61; 95%CI 1.37–1.97) and during night time (odds ratio 1.52; 95%CI 1.27–1.82) and use of intravenous thrombolysis (odds ratio 1.28; 95%CI 1.08–1.50). Conclusion: Door-to-groin time was especially relevant for outcome of comprehensive stroke center patients, whereas door-to-groin time was much shorter in primary stroke center patients. Clinical Trial Registration: https://clinicaltrials.gov/ct2/show/NCT03356392 . Unique identifier NCT03356392
- 20 January 2021
- Published by SAGE Publications in International Journal of Stroke
- Vol. 16 (8) , 953-961
How do treatment times impact on functional outcome in stroke patients undergoing thrombectomy in Germany? Results from the German Stroke Registry
Background: Functional outcome post-stroke depends on time to recanalization. Effect of in-hospital delay may differ in patients directly admitted to a comprehensive stroke center and patients transferred via a primary stroke center. We analyzed the current door-to-groin time in Germany and explored its effect on functional outcome in a real-world setting. Methods: Data were collected in 25 stroke centers in the German Stroke Registry-Endovascular Treatment a prospective, multicenter, observational registry study including stroke patients with large vessel occlusion. Functional outcome was assessed at three months by modified Rankin Scale. Association of door-to-groin time with outcome was calculated using binary logistic regression models. Results: Out of 4340 patients, 56% were treated primarily in a comprehensive stroke center and 44% in a primary stroke center and then transferred to a comprehensive stroke center (“drip-and-ship” concept). Median onset-to-arrival at comprehensive stroke center time and door-to-groin time were 103 and 79 min in comprehensive stroke center patients and 225 and 44 min in primary stroke center patients. The odds ratio for poor functional outcome per hour of onset-to-arrival-at comprehensive stroke center time was 1.03 (95%CI 1.01–1.05) in comprehensive stroke center patients and 1.06 (95%CI 1.03–1.09) in primary stroke center patients. The odds ratio for poor functional outcome per hour of door-to-groin time was 1.30 (95%CI 1.16–1.46) in comprehensive stroke center patients and 1.04 (95%CI 0.89–1.21) in primary stroke center patients. Longer door-to-groin time in comprehensive stroke center patients was associated with admission on weekends (odds ratio 1.61; 95%CI 1.37–1.97) and during night time (odds ratio 1.52; 95%CI 1.27–1.82) and use of intravenous thrombolysis (odds ratio 1.28; 95%CI 1.08–1.50). Conclusion: Door-to-groin time was especially relevant for outcome of comprehensive stroke center patients, whereas door-to-groin time was much shorter in primary stroke center patients. Clinical Trial Registration: https://clinicaltrials.gov/ct2/show/NCT03356392 . Unique identifier NCT03356392